Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to investigate the effect of concurrent chemoradiation therapy on respiratory muscle performance, lung function and functional capacity in patients with local esophagus cancer.
This is a prospective observational study design. A total of 45 patients with newly diagnosed esophageal cancer will be recruited from the Mackay Memorial Hospital. All tests will be performed at baseline (prior to cancer treatment), weekly during treatment, prior to surgery, and one month after surgery. Tests will include demographic data collection, respiratory muscle performance (maximal inspiratory and expiratory pressure tests combined with diaphragmatic surface electromyography, and pulmonary functional test), dyspnea, and the functional exercise test (6-min walk test).Repeated measure ANOVA will be used for analyzing difference of parameters among various time points.
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Change of maximal inspiratory pressure (MIP) | Change from baseline MIP at the end of each week's treatment, and 2 weeks after the completion of treatment | Baseline, weekly during treatment, and 2 weeks after the completion of treatment |
| Change of diaphragmatic surface electromyography (EMGdi) | Change from baseline EMGdi at the end of each week's treatment, and 2 weeks after the completion of treatment | Baseline, weekly during treatment, and 2 weeks after the completion of treatment |
| Change of forced expiratory volume in one second (FEV1) | Change from baseline FEV1 at the end of each week's treatment, and 2 weeks after the completion of treatment | Baseline, weekly during treatment, and 2 weeks after the completion of treatment |
| Change of forced vital capacity (FVC) | Change from baseline FVC at the end of each week's treatment, and 2 weeks after the completion of treatment | Baseline, weekly during treatment, and 2 weeks after the completion of treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Change of functional exercise capacity | Change from baseline 6-minute walking distance at the end of each week's treatment, and 2 weeks after the completion of treatment | Baseline, weekly during treatment, and 2 weeks after the completion of treatment |
| Change of dyspnea |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
newly diagnosed primary esophageal cancer
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mackay Memorial Hospital | Taipei | Taiwan |
Not provided
| ID | Term |
|---|---|
| D004938 | Esophageal Neoplasms |
| ID | Term |
|---|---|
| D005770 | Gastrointestinal Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Change from baseline Modified Borg Dyspnea score at the end of each week's treatment, and 2 weeks after the completion of treatment |
| Baseline, weekly during treatment, and 2 weeks after the completion of treatment |
| D006258 |
| Head and Neck Neoplasms |
| D004066 | Digestive System Diseases |
| D004935 | Esophageal Diseases |
| D005767 | Gastrointestinal Diseases |